// App-Quantinova.ai

266 : Surrogacy analysis of prostate-specific antigen (PSA) decline for improved overall survival (OS) with enzalutamide (ENZ) in AFFIRM.

Researchers

Presenter

  • Andrew J. Armstrong

Principal Investigators

  • Fred Saad

  • Neal D. Shore

  • Karim Fizazi

  • De Phung

  • Carl Frank Dmuchowski

  • Mohammad Hirmand

  • David Forer

  • Howard I. Scher

  • Johann S. De Bono

Medical Centers

  • Duke Cancer Institute, Duke University and the Department of Defense Prostate Cancer Clinical Trials Consortium, Durham, NC

  • University of Montreal Hospital Center, Montreal, QC, Canada

  • Carolina Urologic Research Center, Myrtle Beach, SC

  • Institut Gustave Roussy, University of Paris Sud, Villejuif, France

  • Astellas Pharma Europe, Leiden, Netherlands

  • Astellas Pharma, Inc., Northbrook, IL

  • Medication, Inc., San Francisco, CA

  • Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan-Kettering Cancer Center, New York, NY

  • The Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom

Locations

  • United States

  • Canada

  • France

  • Netherlands

  • United Kingdom

Companies

  • Astellas Pharma Inc.

  • Medivation, Inc.

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Prostate specific antigen

Drug/Treatment

  • Enzalutamide

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT00974311

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved